PVP XL/ CL/ Cross Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a crosslinked polyvinylpyrrolidone family supplied as a white to off-white hygroscopic powder or friable flakes. The XL designation refers to a standard coarse crospovidone grade, while CL denotes a finer crosslinked povidone grade. Both are practically insoluble in water, ethanol, and methylene chloride and are produced by crosslinking 1-ethenylpyrrolidin-2-one; the Cross descriptor identifies the crosslinked homopolymer backbone. In tablet, capsule, and granule applications, these grades are used as disintegrants at 2% w/w to 5% w/w. For injection and oral liquid formulations, the crosslinked polymer is not used; instead, soluble low-K-value linear povidone grades such as K12 and K17 are supplied because they dissolve in water and can be filtered through 0.22 µm or 0.45 µm filters. The term API in the trade descriptor does not convert crospovidone or povidone into an active moiety for most monographed applications; compendial status remains that of a pharmaceutical excipient.

The product family is controlled against the Crospovidone monograph in USP/NF and PhEur for PVP XL and PVP CL, and against the Povidone monograph for linear K12 and K17 when oral or injectable grade is ordered. Batch release typically includes infrared identification, nitrogen content, loss on drying, sulfated ash, pH of an aqueous suspension, water-soluble substances, vinylpyrrolidone monomer, peroxides, and sieve analysis. For injectable-grade linear povidone, bacterial endotoxin release per USP <85> and subvisible particulate control per USP <788> are added when the finished parenteral is tested. The crosslinked crospovidone grades are not suitable for injection because insoluble swellable particles cannot be removed by terminal sterilizing filtration and would exceed particulate limits in the finished product.

Material handling differs among the grades. PVP XL has lower dusting and better flow in direct-compression blends, while PVP CL can be more electrostatic and requires humidity control below 60% RH to prevent agglomeration on punch faces. The material should be stored in tightly closed containers at controlled room temperature; extended exposure to high humidity increases moisture content and can reduce wicking efficiency. Crosslinked povidone is nonionic and compatible with most common filler-binder systems, but it should not be blended with strong oxidizing agents because residual peroxide species can accelerate oxidation of sensitive actives such as simvastatin or conjugated estrogens.

How Does Crosslinked Povidone Reduce Disintegration Time in Compressed Tablets?

Tablet disintegration is accelerated by liquid uptake through particle wicking and by strain recovery of deformed crospovidone domains after compression. Coarse XL grades with median particle size near 100–130 µm create low-tortuosity channels through the tablet matrix. Fine CL grades with median particle size below 75 µm distribute more uniformly around active pharmaceutical ingredient particles but can fill interparticulate voids under high compression, increasing the distance water must travel before wetting the core. In USP <701> disintegration testing with purified water at 37 ± 2 °C, immediate-release tablets containing 2–5% w/w crospovidone typically disintegrate within 1–5 min; the exact time depends on tablet hardness, porosity, filler solubility, and compression profile.

Crospovidone does not form a continuous viscous gel in contact with water, unlike sodium starch glycolate or hypromellose. The wicking structure remains porous, so drug release is less likely to be retarded by a viscous gel layer. On rotary tablet presses, a coarse XL grade at 4% w/w in a direct-compression dicalcium phosphate anhydrous formula can maintain disintegration below 3 min, but tablet friability may exceed 1.0% if main compression force is pushed above 18 kN. A fine CL grade at the same use level reduces friability but may extend disintegration time when lubricant blending is longer than 5 min in a bin blender at 24 rpm because the fine particles adsorb lubricant and become less effective at wicking. Production batches should be evaluated at a precompression force of 2–5 kN to prevent capping without densifying the tablet enough to destroy wicking channels.

In hard gelatin and hydroxypropyl methylcellulose capsule fill formulations, PVP XL and PVP CL are dry-blended at 2–4% w/w to prevent plug formation and maintain dissolution from the capsule plug. The crosslinked polymer absorbs gastrointestinal fluid at the capsule ends and creates pores in the plug, but its water-insoluble character does not retard capsule shell opening. For lipid or semi-solid capsule fill formulations, crospovidone is not recommended because it settles in high-viscosity vehicles without uniform wetting; colloidal silicon dioxide or fumed silica is preferred for viscosity control. In powder-in-capsule direct fill, fine CL grades may segregate less than coarse XL grades when bulk density differences exceed 0.2 g/mL, but both require periodic uniformity checks because low-bulk-density excipients can increase weight variability in high-speed dosators.

Sieve Fraction and Hydration Capacity in USP/NF Type A and Type B Crospovidone

USP/NF Crospovidone monograph separates Type A and Type B by particle size distribution. Type A retains a larger fraction above 75 µm, while Type B passes a greater fraction through a 75 µm sieve. The coarser Type A material, generally aligned with the PVP XL grade, has a typical bulk density of 0.25–0.40 g/mL and a hydration capacity of 4–7 g water/g polymer. The finer Type B material, often associated with low-fine CL variants, has a higher surface area per unit mass. Particle size is determined by analytical sieving per USP <786> or PhEur 2.9.38, and by laser diffraction per USP <429>. Hydration capacity is measured as grams of water retained per gram of dry polymer after centrifugation under fixed conditions; it is not an equilibrium swelling ratio because a portion of the water is held in interparticulate capillaries and is lost under compression.

The larger particles of PVP XL generate visible porosity in tablets, which aids disintegration but can reduce tensile strength at low compression. PVP CL fills smaller voids and improves surface appearance but can slow water penetration if the tablet is over-lubricated. Grade choice is not based only on median particle size; span, fines content below 10 µm, and hygroscopicity after storage at 40 °C and 75% RH are equally important. Hygroscopicity of crospovidone at 25 °C and 80% RH is moderate compared with sodium starch glycolate. Moisture uptake above 5% w/w may lower the yield pressure of the polymer, reducing its ability to recover after compression. If tablets are packed in PVC blister without desiccant, disintegration time can increase over shelf life. Supplier certificates should report loss on drying and not just water activity, because surface water determines wicking and internal water determines plasticization.

Granulation Processing Windows Are Narrower Than Direct Compression Batches

In high-shear wet granulation, crospovidone is usually split between the intragranular and extragranular fractions. The intragranular fraction helps granule formation and provides internal wicking after drying; the extragranular fraction gives immediate liquid uptake at the tablet surface. A total crospovidone content of 4% w/w split as 2% intragranular and 2% extragranular is a common starting point for acetaminophen and ibuprofen formulations. The intragranular fraction can lose swelling capacity if the wet mass is over-granulated beyond endpoint torque. In a high-shear granulator with impeller speed 300 rpm and chopper speed 1,500 rpm, granulation endpoint commonly occurs within 2–5 min; beyond this window, the crosslinked polymer particles become coated with binder solution and cannot re-establish rapid water uptake after compression. Addition of extragranular crospovidone after dry milling can restore disintegration time to below 5 min in USP <701> testing.

Roller compaction and slugging impose similar constraints. If roll force exceeds 20 kN/cm of roll width, crospovidone particles deform plastically and lose the strain recovery that drives tablet disintegration. Granule porosity after milling is a better predictor of disintegration than total crospovidone concentration. Production-scale batch records show disintegration drift when a fine CL grade is substituted for a coarse XL grade without adjusting compression force and granule size distribution; the smaller particles fill void spaces and increase tablet tensile strength at equal main compression. A change in crospovidone grade is therefore not a direct drop-in substitution and requires re-optimization of lubricant level, granule moisture, and compression profile.

When Injectable-Grade Linear Povidone K12/K17 Replaces Crosslinked Grades in Parenteral Formulations

The crosslinked PVP XL and PVP CL grades are excluded from injectable, ophthalmic, and sterile fluid applications because they are insoluble and elevate subvisible particulate counts. Linear povidone K12 and K17 are water-soluble and can be included in oral solutions, injections, and lyophilized products as stabilization aids. The Povidone monograph specifies K-value, nitrogen content, and moisture limits for these soluble grades; injectable-grade material adds a bacterial endotoxin specification, often ≤0.25 EU/mg for high-purity supply or ≤2.5 EU/g depending on finished dose and manufacturer release protocol. Endotoxin is determined by USP <85> or PhEur 2.6.14. Particulate quality of the finished parenteral is assessed by USP <788> and PhEur 2.9.19. Because linear povidone solutions increase viscosity, terminal filtration through 0.22 µm or 0.45 µm membranes must be validated under production flow rates; membrane fouling can occur at high polymer concentration or low temperature.

For freeze-dried injections, K12 at 1–5% w/v can function as a bulking agent or stabilizer, but it is not a cryoprotectant in the same class as trehalose or sucrose. The glass transition temperature of an amorphous povidone-containing lyophilized cake is lowered by residual moisture; vials should be sealed with cake moisture below 1.0%. High-molecular-weight PVP K90 is generally avoided in parenterals because of higher solution viscosity and slower renal clearance. PVP XL and PVP CL cannot be used in injectable suspensions as suspending agents because they fail insoluble particulate limits and cannot be depyrogenated by dry heat without discoloration. Differences from other products therefore center on solubility, particle size, and regulatory monograph: crospovidone is an insoluble disintegrant, whereas linear povidone is a soluble binder and stabilizer.

In oral liquid preparations, povidone K12 and K17 are used as viscosity modifiers and crystallization inhibitors at concentrations below 5% w/v; above 10% w/v the solution becomes tacky and difficult to pump in high-speed filling lines. The soluble polymer can also inhibit precipitation of poorly soluble actives through hydrogen bonding and hydrophobic interactions, but it is not a substitute for cyclodextrin or surfactant-based solubilization. These oral liquid applications are not interchangeable with crosslinked PVP XL/CL, which would sediment and not dissolve.